Filing Details

Accession Number:
0001567619-21-006128
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-11 17:37:31
Reporting Period:
2021-03-09
Accepted Time:
2021-03-11 17:37:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1512762 Coherus Biosciences Inc. CHRS Biological Products, (No Disgnostic Substances) (2836) 273615821
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1759506 Vladimir Vexler Coherus Biosciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City CA 94065
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-09 24,356 $2.08 89,502 No 4 M Direct
Common Stock Acquisiton 2021-03-09 20,312 $9.30 109,814 No 4 M Direct
Common Stock Acquisiton 2021-03-09 57,812 $10.05 167,626 No 4 M Direct
Common Stock Disposition 2021-03-09 114,240 $16.25 53,386 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-03-09 24,356 $0.00 24,356 $2.08
Common Stock Stock Option (Right to Buy) Disposition 2021-03-09 20,312 $0.00 20,312 $9.30
Common Stock Stock Option (Right to Buy) Disposition 2021-03-09 57,812 $0.00 57,812 $10.05
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2023-02-28 No 4 M Direct
4,688 2027-11-15 No 4 M Direct
17,188 2028-02-01 No 4 M Direct
Footnotes
  1. Includes 52,083 restricted stock units.
  2. The transaction was executed in multiple trades at prices ranging from $16.071 to $16.50, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  3. All of the shares underlying this option are vested and exercisable as of the date hereof.
  4. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from November 15, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.
  5. The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.